L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial.
L-RNA 适配体 CXCL12 抑制剂联合放射疗法和贝伐单抗治疗新诊断的胶质母细胞瘤：I/II 期 GLORIA 试验的扩展。
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-026-71362-7
Giordano Frank A, Layer Julian P, Turiello Roberta, Friker Lea L, Mirallas Oriol, Pregler Barbara E F, Potthoff Anna-Laura, Zeyen Thomas, Weller Johannes, Sperk Elena, Sahm Katharina, Oster Christoph, Kebir Sied, Hambsch Peter, Schäfer Niklas, Kadzik Sebastian, Renovanz Mirjam, Pietsch Torsten, Bisdas Sotirios, Sepúlveda-Sánchez Juan Manuel, Gómez-Puerto Diego, Vieito Maria, Platten Michael, Gkika Eleni, Grauer Oliver M, Tabatabai Ghazaleh, Schneider Matthias, Glas Martin, Seidel Clemens, Herrlinger Ulrich, Hölzel Michael
细胞生物学
XCL1
CXCL1
CXCL12
CXCL1
